SK Plasma Launches High-Dose Thrombocytopenia Treatment for Improved Patient Convenience
Full-Scale Domestic Supply of Revolpak Tablets 75 mg
SK Plasma is expanding the dosage lineup of its thrombocytopenia treatment "Revolpak" to reduce the pill burden for patients requiring higher doses.
SK Plasma announced on September 1 that, following the recent launch of Revolpak 25 mg and 50 mg last month, it is now commencing full-scale domestic supply of the high-dose "Revolpak Tablets 75 mg."
Revolpak is a prescription medication containing eltrombopag olamine, indicated for the treatment of thrombocytopenia. This is the first time a 75 mg dosage has been launched in Korea. Eltrombopag olamine enhances platelet production in the bone marrow, thereby increasing platelet count, and is used in the treatment of chronic immune thrombocytopenia and severe aplastic anemia.
SK Plasma plans to leverage its expertise in blood-related diseases such as albumin and immunoglobulin, aiming to enhance treatment convenience through diversification of dosage and formulation.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Sungjoo Kim, CEO of SK Plasma, stated, "We will reinforce our expertise and portfolio across all areas related to blood-related issues, including plasma-derived therapeutics, and actively incorporate frontline feedback to provide practical benefits to patients."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.